Coverage
-
July 03, 2014
Biopharmacuetical company Affymax Inc. has agreed to pay $6.5 million to settle a class action alleging it knowingly misled investors about the dangers of its drug Omontys, which was recalled in 2013 after being linked to potentially deadly allergic reactions, according to documents filed Thursday in California federal court.
2 other articles on this case.
View all »